Ramelteon: A Novel Hypnotic Lacking Abuse Liability and Sedative Adverse Effects | Anesthesiology | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.  Washington, DC American Psychiatric Association1994;
Ford  DEKamerow  DB Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?  JAMA 1989;2621479- 1484PubMedGoogle ScholarCrossref
Roth  T New developments for treating sleep disorders.  J Clin Psychiatry 2001;62 ((suppl 10)) 3- 4PubMedGoogle ScholarCrossref
IMS Health, Leading 20 products by total US dispensed prescriptions: June 2005 moving annual total. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_73914140_74568514,00.htmlAccessed July 19, 2006
Griffiths  RRJohnson  MW Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.  J Clin Psychiatry 2005;66 (Suppl 9) 31- 41PubMedGoogle Scholar
Griffiths  RRWeerts  EM Benzodiazepine self-administration in humans and laboratory animals: implications for problems of long-term use and abuse.  Psychopharmacology (Berl) 1997;1341- 37PubMedGoogle ScholarCrossref
Longo  LPJohnson  B Addiction, part I: benzodiazepines: side effects, abuse risk, and alternatives.  Am Fam Physician 2000;612121- 2128PubMedGoogle Scholar
Hajak  GMuller  WEWittchen  HUPittrow  DKirch  W Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.  Addiction 2003;981371- 1378PubMedGoogle ScholarCrossref
Office of Applied Studies; Drug Abuse Warning Network, Benzodiazepines in Drug Abuse–Related Emergency Department Visits: 1995-2002.  Rockville, Md Office of Applied Studies, Substance Abuse and Mental Health Services Administration, US Dept of Health and Human Services2004;
Curran  HV Benzodiazepines, memory and mood: a review.  Psychopharmacology (Berl) 1991;1051- 8PubMedGoogle ScholarCrossref
Mintzer  MZGriffiths  RR Selective effects of zolpidem on human memory functions.  J Psychopharmacol 1999;1318- 31PubMedGoogle ScholarCrossref
Rush  CRFrey  JMGriffiths  RR Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.  Psychopharmacology (Berl) 1999;14539- 51PubMedGoogle ScholarCrossref
Curran  HV Psychopharmacological approaches to human memory. In:Gazzaniga  Med. The New Cognitive Neurosciences. Boston, Mass MIT Press2000;797- 804Google Scholar
Stewart  SA The effects of benzodiazepines on cognition.  J Clin Psychiatry 2005;66 ((suppl 2)) 9- 13PubMedGoogle ScholarCrossref
Woods  JHKatz  JLWinger  G Benzodiazepines: use, abuse, and consequences.  Pharmacol Rev 1992;44151- 347PubMedGoogle Scholar
Verster  JCVeldhuijzen  DSVolkerts  ER Residual effects of sleep medication on driving ability.  Sleep Med Rev 2004;8309- 325PubMedGoogle ScholarCrossref
Leipzig  RMCumming  RGTinetti  ME Drugs and falls in older people: a systematic review and meta-analysis, I: psychotropic drugs.  J Am Geriatr Soc 1999;4730- 39PubMedGoogle Scholar
Landi  FOnder  GCesari  MBarillaro  CRusso  ABernabei  R Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study.  J Gerontol A Biol Sci Med Sci 2005;60622- 626PubMedGoogle ScholarCrossref
Hallstrom  C Benzodiazepine Dependence.  New York, NY Oxford University Press1993;
Longo  LPParran  T  JrJohnson  BKinsey  W Addiction, part II: identification and management of the drug-seeking patient.  Am Fam Physician 2000;612401- 2408PubMedGoogle Scholar
Jindal  RDBuysse  DJThase  ME Dr Jindal and colleagues reply [letter].  Am J Psychiatry 2004;1611723Google ScholarCrossref
 Ambien (zolpidem), Sanofi-Aventis. In: Physicians' Desk Reference Greenwood Village, Colo Thomson Micromedex2005;Google Scholar
 2003 National Survey on Drug Use and Health.  Rockville, Md Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA), US Dept of Health and Human Services2004;
Kato  KHirai  KNishiyama  KUchikawa  OFukatsu  KOhkawa  SKawamata  YHinuma  SMiyamoto  M Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.  Neuropharmacology 2005;48301- 310PubMedGoogle ScholarCrossref
Brzezinski  A Melatonin in humans.  N Engl J Med 1997;336186- 195PubMedGoogle ScholarCrossref
Erman  MSeiden  DZammit  GSainati  SZhang  J An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia.  Sleep Med 2006;717- 24PubMedGoogle ScholarCrossref
Roth  TSeiden  DSainati  SWang-Weigand  SZhang  JZee  P Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.  Sleep Med 2006;7312- 318Google ScholarCrossref
Roth  TStubbs  CWalsh  J Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment [published correction appears in Sleep. 2006;29:417].  Sleep 2005;28303- 307PubMedGoogle Scholar
Zammit  GRoth  TErman  MSainati  SWeigand  SZhang  J Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract].  Sleep 2005;28A228- A229Google Scholar
Nishida  NSasaki  MWakasa  YAwasaki  YYamamoto  MYanagita  T Reinforcing effect of ramelteon assessed by intravenous self-administration experiments in rhesus monkeys [abstract].  Sleep 2005;28A45Google Scholar
France  CWeltman  RCruz  CMcMahon  L Ramelteon does not have benzodiazepine agonist-like discriminative stimulus effects in normal or diazepam-dependent rhesus monkeys [abstract].  Sleep 2005;28A45Google Scholar
France  CWeltman  RCruz  C Lack of primary physical dependence effects of ramelteon in rhesus monkeys [abstract].  Sleep 2005;28A45Google Scholar
Griffiths  RRBigelow  GEAtor  NA Principles of initial experimental drug abuse liability assessment in humans.  Drug Alcohol Depend 2003;70 ((suppl 3)) S41- S54PubMedGoogle ScholarCrossref
Griffiths  RRBigelow  GELiebson  IKaliszak  JE Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.  J Pharmacol Exp Ther 1980;215649- 661PubMedGoogle Scholar
Roache  JDGriffiths  RR Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.  J Pharmacol Exp Ther 1985;234120- 133PubMedGoogle Scholar
Mumford  GKRush  CRGriffiths  RR Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.  J Pharmacol Exp Ther 1995;272570- 580PubMedGoogle Scholar
Mintzer  MZFrey  JMYingling  JEGriffiths  RR Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers.  Behav Pharmacol 1997;8561- 574PubMedGoogle ScholarCrossref
Martin  WRSloan  JWSapira  JDJasinski  DR Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.  Clin Pharmacol Ther 1971;12245- 258PubMedGoogle Scholar
Jasinski  D Assessment of the abuse potential of morphine-like drugs (methods used in man). In:Martin  Wed. Drug Addiction I. New York, NY Springer-Verlag1977;197- 258Google Scholar
Griffiths  RRTroisi  JRSilverman  KMumford  GK Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans.  Behav Pharmacol 1993;43- 13PubMedGoogle ScholarCrossref
Griffiths  RRRush  CRPuhala  KA Validation of the multiple-choice procedure for investigating drug reinforcement in humans.  Exp Clin Psychopharmacol 1996;497- 106Google ScholarCrossref
McLeod  DRGriffiths  RRBigelow  GEYingling  JE An automated version of the Digit Symbol Substitution Test (DSST).  Behav Res Methods Instr 1982;14463- 466Google ScholarCrossref
Mintzer  MZGriffiths  RR Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.  Drug Alcohol Depend 1998;5349- 66PubMedGoogle ScholarCrossref
Evans  SMFunderburk  FRGriffiths  RR Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.  J Pharmacol Exp Ther 1990;2551246- 1255PubMedGoogle Scholar
Mintzer  MZGriffiths  RR Alcohol and triazolam: differential effects on memory, psychomotor performance and subjective ratings of effects.  Behav Pharmacol 2002;13653- 658PubMedGoogle ScholarCrossref
Roache  JDGriffiths  RR Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.  J Pharmacol Exp Ther 1987;243978- 988PubMedGoogle Scholar
Griffiths  RRMcLeod  DRBigelow  GELiebson  IARoache  JD Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.  Psychopharmacology (Berl) 1984;84147- 154PubMedGoogle ScholarCrossref
Iguchi  MYHandelsman  LBickel  WKGriffiths  RR Benzodiazepine and sedative use/abuse by methadone maintenance clients.  Drug Alcohol Depend 1993;32257- 266PubMedGoogle ScholarCrossref
Seivewright  NDougal  W Withdrawal symptoms from high dose benzodiazepines in poly drug users.  Drug Alcohol Depend 1993;3215- 23PubMedGoogle ScholarCrossref
Strang  JSeivewright  NFarrell  M Oral and intravenous abuse of benzodiazepines. In:Hallstrom  Ced. Benzodiazepine Dependence. New York, NY Oxford University Press1993;128- 142Google Scholar
Darke  SRoss  JCohen  J The use of benzodiazepines among regular amphetamine users.  Addiction 1994;891683- 1690PubMedGoogle ScholarCrossref
San  LTorrens  MTato  JCastillo  Cde la Torre  RArranz  B Monitoring patterns of substance use in drug-dependent patients.  J Subst Abuse Treat 1998;15425- 430PubMedGoogle ScholarCrossref
Bleich  AGelkopf  MSchmidt  VHayward  RBodner  GAdelson  M Correlates of benzodiazepine abuse in methadone maintenance treatment: 1 year prospective study in an Israeli clinic.  Addiction 1999;941533- 1540PubMedGoogle ScholarCrossref
Preston  KLWolf  BGuarino  JJGriffiths  RR Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.  J Pharmacol Exp Ther 1992;262707- 720PubMedGoogle Scholar
Rush  CRBaker  RWWright  K Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.  Psychopharmacology (Berl) 1999;144220- 233PubMedGoogle ScholarCrossref
Olsen  RW GABA. In:Davis  KLCharney  DCoyle  JTNemeroff  Ceds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa Lippincott Williams & Wilkins2002;159- 168Google Scholar
Turek  FWGillette  MU Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists.  Sleep Med 2004;5523- 532PubMedGoogle ScholarCrossref
Original Article
October 2006

Ramelteon: A Novel Hypnotic Lacking Abuse Liability and Sedative Adverse Effects

Author Affiliations

Author Affiliations: Departments of Psychiatry and Behavioral Sciences (Drs Johnson, Suess, and Griffiths) and Neuroscience (Dr Griffiths), The Johns Hopkins University School of Medicine, Baltimore, Md.

Arch Gen Psychiatry. 2006;63(10):1149-1157. doi:10.1001/archpsyc.63.10.1149

Context  Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment. Most approved insomnia medications have potential for abuse and cause motor and cognitive impairment.

Objective  To evaluate the potential for abuse, subjective effects, and motor and cognitive–impairing effects of ramelteon compared with triazolam, a classic benzodiazepine sedative-hypnotic drug.

Design  In this double-blind crossover study, each participant received oral doses of ramelteon (16, 80, or 160 mg), triazolam (0.25, 0.5, or 0.75 mg), and placebo during approximately 18 days. All participants received each treatment on different days. Most outcome measures were assessed at 0.5 hours before drug administration and repeatedly up to 24 hours after drug administration.

Setting  Residential research facility.

Participants  Fourteen adults with histories of sedative abuse.

Main Outcome Measures  Subject-rated measures included items relevant to potential for abuse (eg, drug liking, street value, and pharmacological classification), as well as assessments of a broad range of stimulant and sedative subjective effects. Observer-rated measures included assessments of sedation and impairment. Motor and cognitive performance measures included psychomotor and memory tasks and a standing balance task.

Results  Compared with placebo, ramelteon (16, 80, and 160 mg) showed no significant effect on any of the subjective effect measures, including those related to potential for abuse. In the pharmacological classification, 79% (11/14) of subjects identified the highest dose of ramelteon as placebo. Similarly, compared with placebo, ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure. In contrast, triazolam showed dose-related effects on a wide range of subject-rated, observer-rated, and motor and cognitive performance measures, consistent with its profile as a sedative drug with abuse liability.

Conclusion  Ramelteon demonstrated no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose and may represent a useful alternative to existing insomnia medications.